ACTA MEDICINAE 2/2012 ONKOLOGIE

ACTA MEDICINAE 2/2012 ONKOLOGIE
Kompletní literatura
2
Informační zázemí onkologických screeningových programů ČR a jejich výsledky
hodnocené z mezinárodního hlediska
2
Chemoterapie a hormonální léčba karcinomu prsu
3
Prevence nevolnosti a zvracení po chemoterapii
4
Novinky v léčbě karcinomu prsu
5
Projekt 35 – příliš mladá na karcinom prsu?
5
Nejnovější poznatky v léčbě pokročilého hepatocelulárního karcinomu
5
Biologická léčba nádorů ledvin
6
Karcinom plic
7
Komplexní léčba metastatického kolorektálního karcinomu
7
Karcinom žaludku
7
Germinální nádory varlat – přehled diagnostiky a terapie
8
Současné možnosti léčby karcinomu slinivky břišní
9
Výživa onkologického pacienta
9
Současné možnosti léčby průlomové bolesti onkologických pacientů
10
Léčba olanzapinem u pacientů se schizofrenií
10
Depresivní porucha a její léčba
11
Role mikroRNA při vzniku nádorů a možnosti jejich využití v léčbě
kolektiv autorů
MUDr. Katarína Petráková Klinika komplexní onkologické péče MOU, Brno
doc. MUDr. Miroslav Tomíška, CSc. Interní hematologická a onkologická klinika LF MU a FN, Brno
MUDr. Michal Vočka | MUDr. Zuzana Ušiaková | prof. MUDr. Luboš Petruželka, CSc.
Onkologická klinika 1. LF UK a VFN a ÚVN, Praha
doc. MUDr. Petra Tesařová, DrSc. Onkologická klinika 1. LF UK a VFN, Praha
prof. MUDr. Jitka Abrahámová, DrSc. Onkologická klinika 1. LF UK
a Thomayerovy nemocnice s poliklinikou, KOC (NNB, VFN a TN), Praha
doc. MUDr. Jindřich Fínek, Ph.D. Onkologické a radioterapeutické oddělení FN a LF UK, Plzeň
MUDr. Bohdan Kadlec | prof. MUDr. Jana Skřičková, CSc. | MUDr. Marcela Tomíšková
Klinika nemocí plicních a tuberkulózy LF MU a FN, Brno
MUDr. Igor Kiss, Ph.D. | MUDr. Jana Halámková
Klinika komplexní onkologické péče MOU a LF, Brno
MUDr. Jiří Tomášek Klinika komplexní onkologické péče MOU, Brno
MUDr. Tomáš Büchler, Ph.D. | prof. MUDr. Jitka Abrahámová, DrSc.
Onkologická klinika Fakultní Thomayerovy nemocnice s poliklinikou a 1. LF UK, Praha
MUDr. Michal Vočka | prof. MUDr. Luboš Petruželka, CSc.
Onkologická klinika 1. LF UK a VFN a ÚVN, Praha
doc. MUDr. Miroslav Tomíška, CSc. Interní hematologická a onkologická klinika LF MU a FN, Brno
MUDr. Ondřej Sláma, Ph.D. Ambulance podpůrné a paliativní onkologie,
Klinika komplexní onkologické péče MOU, Brno
doc. MUDr. Klára Látalová, Ph.D. Klinika psychiatrie FN Olomouc, LF UP, Olomouc
prof. MUDr. Ján Praško, CSc. | doc. MUDr. Klára Látalová, Ph.D.
Klinika psychiatrie FN Olomouc, LF UP, Olomouc
prof. Ing. Jaroslav Petr, DrSc. Výzkumný ústav živočišné výroby, Praha
Informační zázemí onkologických screeningových programů
ČR a jejich výsledky hodnocené z mezinárodního hlediska
kolektiv autorů
1 Prorok, P. – Kramer, B. – Gohagan, J.: Screening Theory and Study Design: The Basics. In: Kramer, B. – Gohagan, J. – Prorok, P. (eds.): Cancer
Screening – Theory and Practise. New York, Marcel Dekker, 1999.
2 Rada Evropské unie: Doporučení rady ze dne 2. prosince 2003 o screeningu
zhoubných nádorů. On-line ec.europa.eu/health/ph_information/ dissemination/diseases/docs/cancer_recommendation_cs.pdf, cit. 20. 8. 2008.
3 Arbyn, M. – Anttila, A. – Jordan, J. – Ronco, G. – Schenck, U. – Segnan N., et al.: European guidelines for quality assurance in cervical can­
cer screening, 2nd ed. Luxembourg, European Communities, 2008.
4 Perry, N. – Broeders, M. – de Wolf, C. – Tornberg, S. – Holland, R. –
von Karsa, L., et al. (eds.): European guidelines for quality assurance in
breast cancer screening and diagnosis, 4th ed. Luxembourg, Office for
Official Publications of the EC, 2006.
5 Segnan, N. – Patnick, J. – von Karsa, L. (eds.): European guidelines for
quality assurance in colorectal cancer screening and diagnosis. Luxembourg, Publications Office of the European Union, 2010.
6 Dušek, L. – Mužík, J. – Kubásek, M. – Koptíková, J. – Žaloudík, J. –
Vyzula, R.: Epidemiologie zhoubných nádorů v České republice. On-line
http://www.svod.cz. 2007, cit. 2009.
7 Dušek, L. – Mužík, J. – Kubásek, M. – Koptíková, J. – Žaloudík, J. –
Vyzula, R.: Epidemiologie zhoubných nádorů v České republice. 2005,
www.svod.cz, cit. 14. 9. 2009.
8 Pavlík, T. – Dušek, L. – Májek, O. – Žaloudík, J.: Five-Year Survival
Rates of Cancer Patients in the Czech Republic. In: Dušek, L., et al.
(eds.): Czech Cancer Care in Numbers 2008–2009. Praha, Grada Publi­­
shing, 2009.
9 Pavlik, T. – Majek, O. – Muzik, J. – Koptikova, J. – Slavicek, L. – Finek,
J., et al.: Estimating the number of colorectal cancer patients treated
with anti-tumour therapy in 2015: the analysis of the Czech National
Cancer Registry. BMC Public Health, 2012, 12 (1), s. 117.
10Nystrom, L. – Andersson, I. – Bjurstam, N. – Frisell, J. – Nordenskjold,
B. – Rutqvist, L. E.: Long-term effects of mammography scree­ning: updated overview of the Swedish randomised trials. Lancet, 2002, 359
(9310), s. 909–919.
11Mandel, J. S. – Bond, J. H. – Church, T. R. – Snover, D. C. – Bradley, G.
M. – Schuman, L. M., et al.: Reducing mortality from colorectal cancer
by screening for fecal occult blood. Minnesota Colon Cancer Control
Study. N Engl J Med, 1993, 328 (19), s. 1365–1371.
12Hakama, M. – Rasanen-Virtanen, U.: Effect of a mass screening
pro­gram on the risk of cervical cancer. Am J Epidemiol. 1976, 103 (5),
s. 512–517.
13Day, N. – Williams, D. – Khaw, K.: Breast cancer screening programmes:
the development of a monitoring and evaluation system. Br J Cancer,
1989, s. 954–958.
14Lieberman, D. – Nadel, M. – Smith, R. A. – Atkin, W. – Duggirala,
S. B. – Fletcher, R., et al.: Standardized colonoscopy reporting and
data system: report of the Quality Assurance Task Group of the National Colorectal Cancer Roundtable. Gastrointest Endosc, 2007, 65 (6),
s. 757–766.
15Vainio, H. – Bianchini, F. (eds.): Breast Cancer Screening. Lyon,
IARCPress, 2002.
16Althuis, M. D. – Dozier, J. M. – Anderson, W. F. – Devesa, S. S. – Brinton, L. A.: Global trends in breast cancer incidence and mortality
1973–1997. Int J Epidemiol, 2005, 34 (2), s. 405–412.
17Brenner, H. – Gondos, A. – Arndt, V.: Recent major progress in longterm cancer patient survival disclosed by modeled period analysis.
J Clin Oncol, 2007, 25 (22), s. 3274–3280.
18de Vries, E. – Karim-Kos, H. E. – Janssen-Heijnen, M. L. – Soerjomataram, I. – Kiemeney, L. A. – Coebergh, J. W.: Explanations for worse­ning
cancer survival. Nat Rev Clin Oncol, 2010, 7 (1), s. 60–63.
19Karsa, L. – Anttila, A. – Ronco, G. – Ponti, A. – Malila, N. – Arbyn, M., et
al.: Cancer Screening in the European Union: Report on the implementa­
tion of the Council Recommendation on cancer screening. Luxembourg,
European Communities, 2008.
20Zavoral, M. – Suchanek, S. – Zavada, F. – Dusek, L. – Muzik, J. – Sei­
fert, B., et al.: Colorectal cancer screening in Europe. World J Gastro­
enterol, 2009, 15 (47), s. 5907–5915.
21Majek, O. – Danes, J. – Skovajsova, M. – Bartonkova, H. – Buresova,
L. – Klimes, D., et al.: Breast cancer screening in the Czech Republic:
time trends in performance indicators during the first seven years of
the organised programme. BMC Public Health, 2011, 11, s. 288.
22Mansmann, U. – Crispin, A. – Henschel, V. – Adrion, C. – Augustin,
V. – Birkner, B., et al.: Epidemiology and quality control of 245 000
outpatient colonoscopies. Dtsch Arztebl Int, 2008, 105 (24), s. 434–440.
23Kaminski, M. F. – Regula, J. – Kraszewska, E. – Polkowski, M. –
Wojciechowska, U. – Didkowska, J., et al.: Quality indicators for colo­
no­scopy and the risk of interval cancer. N Engl J Med, 2010, 362 (19),
s. 1795–1803.
Chemoterapie a hormonální léčba karcinomu prsu
MUDr. Katarína Petráková Klinika komplexní onkologické péče MOU, Brno
1 Kaufmann, M. – von Minckwitz, G. – Bear, H. D., et al.: Recommendation from an international expert panel on the use of neoadjuvant
(primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol, 2007, 18 (12), s. 1927–1934.
2 Ring, A. E. – Smith, I. E. – Ashley, S., et al.: Oestrogen receptor status,
pathological complete response and prognosis in patients receiving
neoadjuvant chemotherapy for early breast cancer. Br J Cancer, 2004,
91, s. 2012–2017.
3 Goldhirsch, A. – Wood, W. C. – Gelber, R. D., et al.: Strategies for subtypes-dealing with the diversity of breast cancer: Highlights of the
St.Gallen International Expert Consensus on the Primary Therapy of
Early Breast Cancer 2011. Ann Oncol, 2011, 22 (8), s. 1736–1747.
4 Fischer, B. – Neony, J. H. – Bryant, J., et al.: Treatment of lymphnode-negative, oestrogen receptor positive breast cancer:long-term
findings from National Surgical Adjuvant Breast and Bowel Project
randomised clinical trials. Lancet, 2004, 364, s. 858–868.
5 Albain, K. – Barlow, W. – O´Malley, F., et al.: Concurrent (CAFT) versus
sequential (CAF-T) chemohormonal therapy (cyclophosphamid, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal,
node-positive, estrogen (ER) and/or progesteron (PgR) receptor-positive breast cancer: mature outcomes and new biological correlates on
phase III intergroup trial 0100 (SWOG.-8814). Breast Cancer Res Treat,
2004, 88 (dopl. 1), abs. 37.
6 Henderson, I. C. – Berry, D. A. – Demetri, G. D., et al.: Improved
ACTA MEDICINAE 2/2012 ONKOLOGIE Kompletní literatura
outco­mes from adding sequential paclitaxel, but not from escalating doxorubicin dose in an adjuvant chemotherapy regiment for patiens with node positive primary breast cancer. J Clin Oncol, 2003, 21,
s. 976–983.
7 Roche, H. – Fumoleau, P. – Spielman, M., et al.: Sequential adjutant
epirubicin-based and docetaxel chemotherapy for node-positi­ve
breast cancer patients:the FNCLCC PACS 01 Trial. J Clin Oncol, 2006,
24 (36), s. 5664–5671.
8 Francis, P. – Crown, J. – Di Leo, A., et al.: BIG 02-98 Collaborative Group.
Adjutant chemotherapy with sequential or concurrent anthracycline
and docetaxel: Breast International Group 02-98 randomized trial.
J Natl Cancer Inst, 2008, 100 (2), s. 121–133.
9 Martin, M. – Pienkowski, T. – Mackey, J., et al.: Breast Cancer International Researche Group 001 Investigators. Adjutant docetaxel for
node-positive breast cancer. N Engl J Med, 2005, 352 (22), s. 2302–2313.
10Jones, et al.: Breast Cancer Res Treat, 2007, 106 (dopl. 1), s. S5, abs. 12.
11Cuzik, J. – Ambroisine, L. – Davidson, N., et al.: Use of luteinising-hor­
mone-realising hormone agonists as adjuvant treatment in preme­
no­pausal patiens with hormone-receptor-positive breast cancer:
a metaanalysis of individual patient data from randomised adjuvant
trials. Lancet, 2007, 369, s. 1711–1723.
12Peto, R. – Davies, C., and the ATLAS investigators: ATLAS (Adjutant
Ta­moxifen Longer Against Shorter):international randomised trial of
10 vs 5 years of adjutant tamoxifen among 11,500 women: prelimina­
ry results. Breast Cancer Res Treat, 2007, 106 (dopl. 1), s. S00, abs. 48.
13Rea, D. W. – Hanley, K. – Marshall, M., et al.: aTTom (adjutant Tamoxi­
fen-To offer more?): Randomised trial of 10 versus 5 years of adjutant
tamoxifen among 6,934 women with estrogen receptor positive (ER+)
or ER untested breast cancer- Preliminary results. Proc Am Soc Clin
­Oncol, 2­ 008, abs. 513.
14Forbes, J. F. – Cuzick, J. – Buzdar, A., et al.: Effect of anastrozole
and tamoxifen as adjuvant treatment for early-stage breast cancer:
100-month analysis of the ATAC trial. Lancet Oncol, 2008, 9, s. 45–53.
15Coates, A. S. – Kashaviah, A. – Thurlimann, B., et al.: Five years of le­
trozole compared with tamoxifen as initial adjutant therapy for post­
menopausal women with endocrine-responsive early breast cen­cer:
update of study BIG 1-98. J Clin Oncol, 207, 25, s. 486–492.
16Goss, P. E. – Unyle, J. N. – Martino, S., et al.: Randomized trial of
letrozole following tamoxifen as extended adjutant therapy in
receptor-positive breast cancer: update findings from NIC CTG MA17.
J Natl Cancer Indy, 2005, 97, s. 1262–1271.
17Carrick, S. – Parker, S. – Wilcken, N., et al.: Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Databáze
Syst Rev, 2005, 2, Art No. CD003372, doi: 10.1002/14651858.
18Bruzzi, P. – Del Mastro, L. – Formani, M. P., et al.: Objective response to
chemotherapy as a potential surrogate and point of survival in metastatic breast cancer patiens. J Clin Oncol, 2005, 23, s. 5117–5125.
19Greenberg, P. A. – Hortobagyi, G. N. – Smith, T. L., et al.: Long-term
follow-up of patiens with complete remission following combina­
tion chemotherapy for metastatic breast cancer. J Clin Oncol, 1996,
14, s. 2197–2205.
20Nabholtz, J. M. – Falkon, C. – Campos, D., et al.: Docetaxel and do­
xo­rubicin compared with doxorubicin and cyclophosphamide as
first-line chemotherapy for metastatic breast cancer:results of a rando­
mi­zed, multicenter, phase III. trial. J Clin Oncol, 2003, 21, s. 968–975.
21Jassem, J. – Pienkowski, T. – Pluzanska, A., et al.: Doxorubicin and
pa­cli­taxel versus fluorouracil, doxorubicin and cyclophosphamide as
first-line therapy for women with metastatic breast cancer:final re­
sults of a randomised phase III multicenter trial. J Clin Oncol, 2001, 19,
s. 1707–1715.
22Boneneterre, J. – Thurlimann, B. – Robertson, J. F., et al.: Anastrozol versus tamoxifen in first-line therapy for advanced breast cancer
in 668 postmenopausal women:results of the Tamoxifen or Arimidex
Randomized Group Efficacy and Tolerability study. J Clin Oncol, 200,
18, s. 3748–3757.
23Nabholtz, J. M. – Buzdar, A. – Pollak, M., et al.: Anastrozol is superior to
tamoxifen as first-line therapy for advanced breast cancer in postme­
nopausal women:results of a North American multicenter randomized
trial. Arimidex Study Group. J Clin Oncol, 2000, 18, s. 3758–3767.
24Howell, A. – Robertson, J. F. – Abram, P., et al.: Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine
therapy: a multinational, double-blind, randomised trial. J Clin Oncol,
2004, 22, s. 1605–1613.
25Klijn, J. G. – Blamey, R. W. – Boccardo, F., et al.: Combined tamoxifen
and luteinizing hormone-releasing hormone (LHRH) agonist versus
LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomised trials. J Clin Oncol, 2001, 19, s. 343–353.
Prevence nevolnosti a zvracení po chemoterapii
doc. MUDr. Miroslav Tomíška, CSc. Interní hematologická a onkologická klinika LF MU a FN, Brno
1 Grunberg, S. – Deuson, R. R. – Mavros, P., et al.: Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Can­
cer, 2004, 100, s. 2261–2268.
2 Roila, F. – Herrstedt, J. – Aapro, M., et al.: Guideline update for MASCC
and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus confe­
rence. Ann Oncol, 2010, 21 (dopl. 5), s. v232–v243.
3 Ettinger, D. S., and Pannel Members: NCCN Clinical Practice Guidelines in
Oncology. Version I.2012. //www.nccn.org/professionals/physician_gls/ .
4 Ellebaek, E. – Herrstedt, J.: Optimizing antiemetic therapy in multipleday and multiple cycles of chemotherapy. Current Opinion in Suppor­
tive and Palliative Care, 2008, 2, s. 28–34.
5 Schwartzberg, L. – Szabo, S. – Gilmore, J., et al.: Likelihood of a subsequent chemotherapy-induced nausea and vomiting (CINV) event
in patients receiving low, moderately and highly emetogenic chemotherapy (LEC, MEC, HEC). Curr Med Res Opinion, 2011, 27, s. 837–845.
6 Hesketh, P. J. – Aapro, M. – Street, J. C. – Carides, A. D.: Evaluation of
risk factors predictive of nausea and vomiting with current standard-
-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care
Cancer, 2010, 18 (9), s. 1171–1177.
7 Warr, D. G. – Street, J. C. – Carides, A. D.: Evaluation of risk factors
predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients
receiving adriamycin-cyclophosphamide-based chemotherapy. Sup­
port Care Cancer, 2011, 19 (6), s. 807–813.
8 Rojas, C. – Thomas, A. G. – Alt, J., et al.: Palonosetron triggers 5-HT3
receptor internalization and causes prolonged inhibition of receptor
function. European J Pharmacol, 2010, 626, s. 193–199.
9 Navari, R. M.: Prevention of emesis from multiple-day and high-dose
chemotherapy regimens. J Nation Compr Cancer Network, 2007, 5,
s. 51–59.
10Warr, D. G. – Grunberg, S. M. – Gralla, R. J. – Hesketh, P. J. – Roila, F. –
deWit, R., et al.: The oral NK1 antagonist aprepitant for the prevention
of acute and delayed chemotherapy-induced nausea and vomi­ting:
Pooled data from 2 randomised, double-blind, placebo controlled
ACTA MEDICINAE 2/2012 ONKOLOGIE Kompletní literatura
­trials. E­ ur J Cancer, 2005, 41, s. 1278–1285.
11Botrel, T. E. – Clark, O. A. – Clark, L., et al.: Efficacy of palonosetron
(PAL) compared to other serotonin inhibitors (5-HT3R) in preventing
chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis. Support Care in Cancer, 2011, 19,
s. 823–832.
12Rapoport, B. L. – Jordan, K. – Boice, J. A., et al.: Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated
with broad spectrum of moderately emetogenic chemotherapies and
tumor types: a randomized, double blind study. Support Care Cancer,
2009, doi: 10.1007/s00520-009-0680-9.
13Grunberg, S. – Clark-Snow, R. A. – Koeller, J.: Chemotherapy-induced
nausea and vomiting: contemporary approaches to optimal management. Support Care Cancer, 2010, 18 (dopl. 1), s. S1–S10.
14Bash, E. – Prestrud, A. A. – Hesketh, P. J. – Kris, M. G., et al.: Antieme­
tics: American Society of Clinical Oncology Clinical Practice Guideline
Update. J Clin Oncol, 2011, doi: 10.1200/JCO.2010.34.4614.
Novinky v léčbě karcinomu prsu
MUDr. Michal Vočka | MUDr. Zuzana Ušiaková | prof. MUDr. Luboš Petruželka, CSc.
Onkologická klinika 1. LF UK a VFN a ÚVN, Praha
1 Petruželka, L.: Současné možnosti a nové perspektivy systémové léčby
karcinomu prsu. Klin Farmakol Farm, 21, 2007, s. 11–17.
2 Petruželka, L.: Karcinom prsu – jak dál v diagnostice a léčbě ve světle
nových možností. Vnitř Lék, 53, 2007, s. 22–23.
3 Petruželka, L.: Nové možnosti léčby ErbB2 a hormonálně dependentních karcinomů prsu. Klin. Farmakoter, 2012, v tisku.
4 Higgins, M. J. – José Baselga, J.: Targeted therapies for breast cancer.
J Clin Invest, 2011, 121 (10), s. 3797–3803.
5 Tang, R. Y. – Finn, R. S.: Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer. British Journal of Cancer,
2012, 106, s. 6–13.
6 Slamon, D. J. – Leyland-Jones, B. – Shak, S., et al.: Use of chemothe­
rapy plus a monoclonal antibody against HER2 for metastatic breast
cancer that overexpresses HER2. N Engl J Med, 344, 2001, s. 783–790.
7 Pegram, M. D. – Konecny, G. E. – O’Callaghan, C., et al.: Rational combinations of trastuzumab with chemotherapeutic drugs used in the
treatment of breast cancer. J Natl Cancer Inst, 2004, 96, s. 739–745.
8 Petruželka, L.: Biologická léčba karcinomu prsu. Onkologie, 3, 2009,
s. 19–27.
9 Baselga, J. – Cortés, J. – Kim, S.-B., et al.: Pertuzumab plus trastuzu­
mab plus docetaxel for metastatic breast cancer. N Engl J Med, 2011,
366 (2), s. 109–119.
10Lewis Phillips, G. D. – Li, G. – Dugger, D. L., et al.: Targeting HER2-po­
si­tive breast cancer with trastuzumab-DM1, an antibody-cytotoxic
drug conjugate. Cancer Res, 2008, 68, s. 9280–9290.
11Beeram, M. – Burris, H. A. – Modi, S. – Birkner, M. – Girish, S. – Tibbitts, J.: A phase I study of trastuzumab-DM1 (T-DM1), a fi rst in class
HER2 antibody-drug conjugate (ADC), in patients (pts) with advanced
HER2+ breast cancer (BC). Proc Am Soc Clin Oncol, 2008, 26, abstr. 1028.
12Krop, I. E. – Mita, M. – Burris, H. A., et al.: A phase I study of weekly dosing of trastuzumab- DM1 (T-DM1) in patients with advanced
HER2+ breast cancer. Prezentováno: 31st Annual San Antonio Breast
Cancer Symposium; 10.–14. 12. 2008; San Antonio, TX. Abstrakt 3136.
13Vogel, C. L. – Burris, H. A. – Limentani, S., et al.: A phase II study of
trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC),
in patients (pts) with HER2+ metastatic breast cancer (MBC): final results. Proc Am Soc Clin Oncol, 2009, 27 (dopl. 15), abstr. 1017.
14Alvarez, R. H. – Valero, V. – Gabriel, N. – Hortobagyi, G. N.: Emerging
Targeted Therapies for Breast Cancer. J Clin Oncol, 2010, 28, s. 3366–3379.
15Jordan, M. A. – Kamath, K. – Manna, T., et al.: The primary antimitotic
mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther, 2005, 4, s. 1086–1095.
16Okouneva, T. – Azarenko, O. – Wilson, L., et al.: Inhibition of centromere dynam-ics by eribulin (E7389) during mitotic metaphase. Mol
Cancer Ther, 2008, 7, s. 2003–2011.
17Towle, M. J. – Salvato, K. A. – Budrow, J., et al.: In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res, 2001, 61, s. 1013–1021.
18Goel, S. – Mita, A. C. – Mita, M., et al.: A Phase I study of eribulin mesy­
la­te (E7389), a mechanistically novel inhibitor of microtubule dyna­
mics, in patients with advanced solid tumors. Clin Cancer Res, 2009,
15, s. 4207–4212.
19Tan, A. R. – Rubin, E. H. – Walton, D. C., et al.: Phase I study of eribulin
mesylate (E7389) administered once every 21 days in patients with
advanced solid tumors. Clin Cancer Res, 2009, 15, s. 4213–4218.
20Vahdat, L. T. – Pruitt, B. – Fabian, C. J., et al.: Phase II study of eribulin
mesylate, a halichondrin B analog, in patients with metastatic breast
cancer previously treated with an anthracycline and a taxane. J Clin
Oncol, 2009, 27, s. 2954–2961.
21Cortes, J. – Vahdat, L. – Blum, J. L., et al.: Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced
or metastatic breast cancer previously treated with an anthracycline,
a taxane, and capecitabine. J Clin Oncol, 2010, 28, s. 3922–3928.
22Iwata, H. – Aogi, K. – Masuda, N., et al.: Efficacy and safety of eribulin
in Japanese patients (pts) with advanced breast cancer. J Clin Oncol,
2010, 28, s. 1081.
23Twelves, C. – Loesch, D. – Blum, J. L., et al.: A phase III study(EMBRACE)
of eribulin mesylate versus treatment of physician’s choice in patients
with locally recurrent or metastatic breast cancer previously trea­
ted with an anthracycline and a taxane. J Clin Oncol, 2010, 28, abstr.
CRA1004.
24Cigler, T. – Vyndat, L.: Eribulin mesylate for the treatment of breast
cancer. Expert Opin. Pharmacother, 2010, 11 (9), s. 1587–1593.
25Cortes, J. – O’Shaughnessy, J. – Losech, D., et al.: Eribulin monothe­
rapy versus treatment of physician’s choice in patients with metasta­
tic breast cancer (EMBRACE): a phase 3 open-label randomised study.
Lancet, 2011, 377, s. 914–923.
26Hortobagyi, G. N.: Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.
2011 San Antonio Breast Cancer Symposium. Updated late breaking
abstract No. S3-7, 7. 12. 2011.
27Dawood, S. – Broglio, K. – Giordano, S. H., et al.: Prognosis of women
with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol, 2010, 28 (1), s. 92–98.
ACTA MEDICINAE 2/2012 ONKOLOGIE Kompletní literatura
Projekt 35 – příliš mladá na karcinom prsu?
doc. MUDr. Petra Tesařová, DrSc. Onkologická klinika 1. LF UK a VFN, Praha
1 Parkin, D. M.: Cancers attributable to exposure to hormones in the UK
in 2010. Br J Cancer, 2011, 105 (S2), s. S42–S48.
2 Sidoni, A. – Cavaliere, A. – Bellezza, G. – Scheibel, M. – Bucciarelli,
E.: Breast cancer in young women: :clinicopathological features and
biological specificity. Breast, 2003, 12 (4), s. 247–250.
3 Ménard, S. – Casalini, P. – Cascinelli, N. – Balsari, A.: Breast carcinoma
in young patients. Lancet, 2000, 356 (9235), s. 1113, 1123.
4 Jmor, S. – Al-Sayer, H. – Heys, S. D. – Payne, S. – Miller, I. – Ah-See, A. –
Hutcheon, A. – Eremin, O.: Breast cancer in women aged 35 and under: prognosis and survival. J R Coll Surg Edinb, 2002, 47 (5), s. 693–699.
5 Hartmann, S. – Reimer, T. – Gerber, B.: Management of early invasive
breast cancer in very young women (<35 years). Clin Breast Cancer,
2011, 11 (4), s. 196–203.
6 Francis, P. A.: Optimal adjuvant therapy for very young breast cancer
patients. Breast, 2011, 20 (4), s. 297–302.
7 de Bree, E. – Makrigiannakis, A. – Askoxylakis, J. – Melissas, J. – Tsiftsis, D. D.: Pregnancy after breast cancer. A comprehensive review.
J Surg Oncol, 2010, 101 (6), s. 534–542.
8 Hulvat, M. C. – Jeruss, J. S.: Maintaining fertility in young women with
breast cancer. Curr Treat Options Oncol, 2009, 10 (5–6), s. 308–317.
Nejnovější poznatky v léčbě pokročilého
hepatocelulárního karcinomu
prof. MUDr. Jitka Abrahámová, DrSc. Onkologická klinika 1. LF UK
a Thomayerovy nemocnice s poliklinikou, KOC (NNB, VFN a TN), Praha
1 Chen, C. J. – Liang, K. Y. – Chang A. S., et al.: Effects of hepatitis B virus, alcohol drinking, cigarette smoking and familial tendency on hepatocellular carcinoma. Hepatology, 1991, 13, s. 398–406.
2 Fattovich, G. – Ribero, M. L. – Pantalena, M., et al.: Hepatitis C virus
genotypes: distribution and clinical significance in patients with cirrhosis type C seen at tertiary referral centres in Europe. J Viral Hepat,
2001, 8, s. 206–216.
3 Wilhelm, S. – Carter, C. – Lynch, M., et al.: Discovery and development
of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug
Discov, 2006, 5, s. 835–844.
4 Llovet, J. M. – Bruix, J.: Novel advancements in the management
of hepatocellular carcinoma in 2008. J Hepatol, 2008, 48 (dopl. 1):
s. S20–S37.
5 Llovet, J. M. – Bruix, J.: Molecular targeted therapies in hepatocellular
carcinoma. Hepatology, 2008, 48, s. 1312–1327.
6 Cheng, A. L. – Kang, Y. K. – Chen, Z., et al.: Efficacy and safety of
sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo
controlled trial. Lancet Oncol, 2009, 10, s. 25–34.
7 Česká onkologická společnost ČLS JEP. Zásady cytostatické léčby
onkologických onemocnění 2011. Dostupné z http://www.linkos.cz/
informace-pro-praxi/zasady-cytostaticke-lecby/ [cit. 4. 5. 2012].
8 Yoon, S. K. – Ye, S. L. – Marrero, J., et al.: GIDEON (Global Investigation of therapeutic DEcision in Hepatocellular Carcinoma and Of its
treatment with sorafeNib) interim results: regional subgroup analysis.
Hepatol Int, 2011, 5, 3–558, FC02–05.
9 Abrahámová, J.: Postavení sorafenibu v současné medikamentózní
léčbě hepatocelulárního karcinomu. In: Farmakoterapie – Léčba hepa­
tocelulárního karcinomu 2011, 2011, 7 (speciální příloha), s. 32–39.
10Kupec, M. – Büchler, T. – Abrahámová, J.: Dlouhodobé přežití pacienta s pokročilým hepatocelulárním karcinomem léčeného sorafenibem.
In: Farmakoterapie – Léčba hepatocelulárního karcinomu 2011, 2011, 7
(speciální příloha), s. 40–41.
11American Society of Clinical Oncology 2012 Gastrointestinal Cancers Sym­
posium, 19.–21. leden 2012, San Francisco, Kalifornie.
Biologická léčba nádorů ledvin
doc. MUDr. Jindřich Fínek, Ph.D. Onkologické a radioterapeutické oddělení FN a LF UK, Plzeň
1 Escudier, B. – Pluzanska, A. – Koralewski, P., et al.: Bevacizumab plus
interferon alfa-2a for treatment of metastatic renal cell carcinoma:
a randomised, double-blind phase III trial. AVOREN Trial investigators.
Lancet, 2007,370 (9605), s. 2103–2111.
2 Rini, B. I. – Halabi, S. – Rosenberg, J. E., et al.: Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in
patients with metastatic renal cell carcinoma: fi nal results of CALGB
90206. J Clin Oncol, 2010, 28 (13), s. 2137–2143.
3 Motzer, R. J. – Michaelson, M. D. – Redman, B. G., et al.: Activity of
SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients
with metastatic renal cell carcinoma. J Clin Oncol, 2006, 24 (1), s. 16–24.
4 Motzer, R. J. – Rini, B. I. – Bukowski, R. M., et al.: Sunitinib in patients with metastatic renal cell carcinoma. JAMA, 2006, 295 (21),
s. 2516–2524.
5 Motzer, R. J. – Hutson, T. E. – Tomczak, P., et al.: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med, 2007, 356
(2), s. 115–124.
6 Motzer, R. J. – Hutson, T. E. – Tomczak, P., et al.: Overall survival and
updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol, 2009, 27 (22),
s. 3584–3590.
7 Hudes, G. – Carducci, M. – Tomczak, P., et al.: Temsirolimus, interfe­
ron alfa, or both for advanced renal-cell carcinoma. Global ARCC Trial.
N Engl J Med, 2007, 356 (22), s. 2271–2281.
8 Sternberg, C. N. – Davis, I. D. – Mardiak, J., et al.: Pazopanib in locally
advanced or metastatic renal cell carcinoma: results of a randomized
phase III trial. J Clin Oncol, 2010, 28 (6), s. 1061–1068, e-pub 25. 1. 2010.
ACTA MEDICINAE 2/2012 ONKOLOGIE Kompletní literatura
9 Escudier, B.. – Eisen, T. – Stadler, W. M., et al.: Sorafenib in advanced
clear-cell renal-cell carcinoma. TARGET Study Group. N Engl J Med,
2007, s. 356 (2), s. 125–134.
10Escudier, B. – Szczylik, C. – Hutson, T. E.: Randomized phase II trial
of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol, 2009, 27 (8),
s. 1280–1289, e-pub 26. 1. 2009. Erratum in: J Clin Oncol, 2009, 27 (13),
s. 2305.
11Stadler, W. M. – Figlin, R. A. – McDermott, D. F., et al.: ARCCS Study
Investigators. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer,
2010, 116 (5), s. 1272–1280.
12Beck, J. – Bajetta, E. – Escudier, B., et al.: A large open-label, non-com­parative, phase III study of the multi-targeted kinase inhibitor
Sorafenib in European patients with advanced renal cell carcinoma.
European Journal of Cancer Suppl, 2007, 5, 300 s. 4506.
13Motzer, R. J. – Escudier, B. – Oudard, S., et al.: Efficacy of everolimus
in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. RECORD-1 Study Group. Lancet, 2008, 372
(9637), s. 449–456.
14SPC Votrient, červen 2010.
15CHMP assessment report/Votrient,14. 6. 2010, www.ema.europa.eu.
16Sternberg, C. N. – Davis, I. D. – Mardiak, J., et al.: Pazopanib in locally
advanced or metastatic renal cell carcinoma: results of a randomized
Phase III trial. J Clin Oncol, 2010, 28, s. 1061–1068.
17Sternberg, C. N. – Szczylik, C. – Lee, E., et al.: A randomized, doubleblind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC).
Presentation at the 45th Annual Meeting American Society of Clinical
Oncology, Orlando, Florida, 29. 5.–2. 6. 2009.
18Hutson, T. E., et al.: Efficacy and safety of pazopanib in patients with
metastatic renal cell carcinoma. J Clin Oncol, 2010, 28 (3), s. 475–480.
Karcinom plic
MUDr. Bohdan Kadlec | prof. MUDr. Jana Skřičková, CSc. | MUDr. Marcela Tomíšková
Klinika nemocí plicních a tuberkulózy LF MU a FN, Brno
1 Adam, Z., et al.: Systémové a paraneoplastické projevy maligních
onemocnění. Vnitř Lék, 2007, 53 (3), s. 253–285.
2 Demedts, I. K. – Vermaelen, K. Y. – van Meerbeeck, J. P.: Treatment of
extensive-stage small cell lung carcinoma: current status and future
prospects. Eur Respir J, 2010, 35, s. 202–215.
3 Gao, G. – Ren, S. – Li, A. – Xu, J. – Xu, Q. – Su, C. – Guo, J. – Deng,
Q. – Zhou, C.: Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-linetreatment of advanced non-small-cell lung cancer with mutated EGFR: Ameta-analysis from six phase III
randomized controlled trials. Int J Cancer, 2011, doi: 10.1002/ijc.27396.
4 Goldstraw, P. – Crowley, J. – Chansky, K. – Giroux, D. J. – Groome, P.
A., et al.: The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol,
2007, 2, s. 706–714.
5 Goldstraw, P. – Crowley, J. J.: The International Association for the
Study of Lung Cancer International Staging Project on Lung Cancer.
J Thorac Oncol, 2006, 1, s. 281–286.
6 Hansen, M.: Paraneoplastic syndromes and tumor markers for small-cell and non-small-cell lung cancer. Curr Opin Oncol, 1990, 2,
s. 345–351.
7 Johnson, B. E. – Janne, P. A.: Basic treatment considerations using chemotherapy for patients with small cell lung cancer. Hematol Oncol Clin
North Am, 2004, 18, s. 309–322.
8 Molina, J. R. – Dusi, A. A. – Jett, J. R.: Advances in Chemotherapy of
Non-small Cell Lung Cancer. CHEST, 2006, 130, s. 1211–1219.
9 Murray, N. – Turrisi, A. T.: A review of first-line treatment for small-cell
lung cancer. J Thorac Oncol, 2006, 1, s. 270–278.
10NSCLC Meta-Analyses Collaborative Group: Chemotherapy in Addition to Supportive Care Improves Survival in Advanced Non-Small- Cell
Lung Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 16 Randomized Controlled Trials. J Clin Oncol, 2008,
26, s. 4617–4625.
11Patel, S. – Macdonald, O. K. – Suntharalingam, M.: Evaluation of the
use of prophylactic cranial irradiation in small cell lung cancer. Cancer,
2009, 115, s. 842–850.
12Pešek, M., et al.: Bronchogenní karcinom. Praha, Galén, 2002.
13Pešek, M. – Skřičková, J. – Kolek, V. – Zatloukal, P. – Petruželka,
L. – Tomíšková, M. – Krákorová, G. – Grygárková, I. – Havel, P. – Zemanová, M. – Minárik, M. – Svobodník, A. – Dušek, L. – Chroust,
K. – Kaisarová, P. – Šlégrová, Z. – Berkovcová, J. – Hajdúch, M.: Výsledky klinického hodnocení účinnosti a toxicity gefitinibu v rámci programu časného přístupu u nemalobuněčného karcinomu plic v České
republice. Studia Pneumologica et Phthiseologica, 2009, 69, 2, s. 61–68.
14Pijls-Johannesma, M. – De Ruysscher, D. – Vansteenkiste, J., et al.:
Timing of chest radiotherapy in patients with limited stage small cell
lung cancer: a systematic review and meta-analysis of randomised
controlled trials. Cancer Treat Rev, 2007, 33, s. 461–473.
15Reck, M. – von Pawel, J. – Zatloukal P., et al.: Phase III trial of cispla­
tin plus gemcitabine with either placebo or bevacizumab as first-line
therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin
­Oncol, 2009, 27 (14), s. 2415.
16Rosell, R. – Carcereny, E. – Gervais, R. – Vergnenegre, A. – Massuti,
B. – Felip, E., et al.: Erlotinib versus standard chemotherapy as first-line
treatment for European patients with advanced EGFR mutation-posi­
tive non-small-cell lung cancer (EURTAC): a multicentre, open-label,
randomised phase 3 trial. Lancet Oncol, 2012, 13, s. 239–246.
17Scott, W. J. – Howington, J. – Feigenberg, S., et al.: Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest, 2007, 132, s. 234S.
18Sculier, J. – Pand Moro-Sibilot, D.: First-and second-line therapy for
advanced nonsmall cell lung cancer. Eur Respir J, 2009, 33, s. 915–930.
19Secretan, B. – Straif, K. – Baan, R., et al.: A review of human carcinogens-Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish.
Lancet Oncol, 2009, 10, s. 1033–1034.
20Shepherd, F. A. – Crowley, J. – van Houtte, P. – Postmus, P. E. – Carney, D., et al.: The International Association for the Study of Lung
Cancer lung cancer staging project:proposals regarding the clinical
staging of small cell lung cancer in the forthcoming (seventh) edition
of the tumor, node, metastasis classification for lung cancer. J Thorac
Oncol, 2007, 2, s. 1067–1077.
21Shepherd, F. A. – Evans, W. K. – Feld, R., et al.: Adjuvant chemothera­
py following surgical resection for small-cell carcinoma of the lung.
J Clin Oncol, 1988, 6, s. 832–838.
22Schneider, B. J.: Management of recurrent small cell lung cancer. J Natl
Compr Canc Netw, 2008, 6, s. 323–331.
23Simon, M. – Argiris, A. – Murren, J. R.: Progress in the therapy of small
cell lung cancer. Crit Rev Oncol Hematol, 2004, 49, s. 119–133.
24Skřičková, J., et al.: Bronchogenní karcinom (41–62). In: Adam, Z. –
Vorlíček, J. – Vaníček, J., et al.: Diagnostické a léčebné postupy u maligních
ACTA MEDICINAE 2/2012 ONKOLOGIE Kompletní literatura
chorob. Grada Publishing, Praha, 2004.
25Yu, J. B. – Decker, R. H. – Detterbeck, F. C. – Wilson, L. D.: Surveillance
epidemiology and end results evaluation of the role of surgery for
stage I small cell lung cancer. J Thorac Oncol, 2010, 5, s. 215–219.
26Zatloukal, P. – Petruželka, L.: Karcinom plic. Praha, Grada, 2001.
27Zhou, C. – Wu, Y. L. – Chen, G. – Feng, J. – Liu, X. Q. – Wang, C., et al.:
Erlotinib versus chemotherapy as first-line treatment for patients with
advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3
study. Lancet Oncol, 2011, 12, s. 735–742.
Komplexní léčba metastatického kolorektálního karcinomu
MUDr. Igor Kiss, Ph.D. | MUDr. Jana Halámková
Klinika komplexní onkologické péče MOU a LF, Brno
1 Software pro vizualizaci onkologických dat (SVOD), www.svod.cz.
2 Screening kolorektálního karcinomu, www.kolorektum.cz.
3 Van Cutsen, E. – Kohne, C. H. – Hitre, E., et al.: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl
J Med, 2009, 360, s. 1408–1417.
4 Hurwitz, H. – Fehrenbacher, L. – Novotny, W., et al.: N Engl J Med,
2004, 350, s. 2335–2342.
5 Saltz, L. B. – Clarke, S. – Díaz-Rubio, E., et al.: Bevacizumab in combination with oxaliplatin based chemotherapy as first line therapy
in metastatic colorectal cancer: a randomized phase III study. J Clin
Oncol, 2008, 26, s. 2013–2019.
6 Bismuth, H. – Adam, R. – Levi F., et al.: Resection of nonresectable liber
metastase from colorectal cancer after neoadjuvant chemothe­ra­py.
Ann Surg, 1996, 224, s. 509–522.
7 Adam, R. – Wicherts, D. A. – de Haas, R. J., et al.: Patient wit initially
unresectable colorectal liver metastase : is there a posibility of cure?
J Clin Oncol, 2009, 27, s. 1829–1835.
8 Nordlinger, B. – Skrbte, H. – Glimelius, B., et al.: Preoperative chemotherapy whith FOLFOX4 and surgery versus surgery alone for resectab­
le liver metastases from colorectal cancer (EORTC Intergroup trial
40983): a randomized controlled trial. Lancet, 2008, 371, s. 1007–1016.
9 Kubala, E. – Bartoš, J. – Petrželka, L., et al.: Safety and effectivness of
bevacizumab in combination with chemotherapy in patients with
metastatic colorectal cancer in eldery population:updated results from
a large Czech observational registry. ASCO GI, 2010.
Karcinom žaludku
MUDr. Jiří Tomášek Klinika komplexní onkologické péče MOU, Brno
1 Cunningham, D. – Allum, W. H. – Stenning, S. P., et al.: Perioperative
chemotherapy versus surgery alone for resectable gastroesophageal
cancer. N Engl J Med, 2006, 355, s. 11–20.
2 Macdonald, J. S. – Smalley, S. R. – Benedetti, J., et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med, 2001,
345, s. 725–730.
3 Wagner, A. D. – Grothe, W. – Haerting, J., et al.: Chemotherapy in ad­
van­ced gastric cancer: a systematic review and meta-analysis based
on aggregate data. J Clin Oncol, 2006, 24, s. 2903–2909.
4 Cunningham, D. – Starling, N. – Rao, S., et al.: Capecitabine and oxa­
liplatin for advanced esophagogastric cancer. N Engl J Med, 2008, 358
(1), s. 36–46.
5 Van Cutsen, E. – Moiseyenko, V. M. – Tjulandin, S., et al.: Phase III stu­
dy of docetaxel and cisplatin plus fluorouracil compared with cisplatin
and fluorouracil as first-line therapy for advanced gastric cancer: a Report of the V325 Study Group. J Clin Oncol, 2006, 24, s. 4991–4997.
6 Ajani, J. A. – Moiseyenko, V. M. – Tjulandin, S., et al.: Quality of life
with docetaxel plus cisplatin and fluorouracil compared with cisplatin
and fluorouracil from a Phase III trial for advanced gastric or gastro­eso­
phageal adenocarcinoma: The V-325 Study Group. J Clin Oncol, 2007,
25, s. 3210–3216.
7 Moehler, M. – Eimermacher, A. – Siebler, J., et al.: Randomized Phase
II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin
(ILF) versus 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated
metastatic gastric cancer. Br J Cancer, 2005, 92, s. 2122–2128.
8 Van Cutsem, E. – Kang, Y. – Chung, H., et al.: Efficacy results from the
ToGA trial: A phase III study of trastuzumab added to standard chemotherapy in firstline human epidermal growth factor receptor 2-positive
advanced gastric cancer. J Clin Oncol, 2009, 27 (15S), LBA4509.
Germinální nádory varlat – přehled diagnostiky a terapie
MUDr. Tomáš Büchler, Ph.D. | prof. MUDr. Jitka Abrahámová, DrSc.
Onkologická klinika Fakultní Thomayerovy nemocnice s poliklinikou a 1. LF UK, Praha
1 Dušek, L. – Mužík, J. – Kubásek, M., et al.: Epidemiologie zhoubných
nádorů v České republice. Masarykova univerzita, 2005, cit. 4. 10. 2012,
http://www.svod.cz.
2 McGlynn, K. A. – Cook, M. B.: Etiologic factors in testicular germ-cell
tumors. Future Oncol, 2009, 5 (9), s. 1389–1402.
3 International Germ Cell Cancer Collaborative Group: Internatio­
nal Germ Cell Consensus Classification: a prognostic factor-based
sta­ging system for metastatic germ cell cancers. J Clin Oncol, 1997,
15, s. 594–603.
4 Capelouto, C. C. – Clark, P. E. – Ransil, B. J., et al.: A review of scrotal violation in testicular cancer: is adjuvant local therapy necessary?
J Urol, 1995, 153, s. 981–985.
5 Abrahámová J.: Léčebné postupy u nepokročilých testikulárních ger­
mi­nálních nádorů neseminomového typu. Klinická onkologie, 2008, 21,
ACTA MEDICINAE 2/2012 ONKOLOGIE Kompletní literatura
3, s. 81–85.
6 Abrahámová J.: Radioterapie germinálních nádorů. In: Abrahámová,
J. – Dušek, L. – Povýšil, C., et al.: Nádory varlat, Grada, 2008, s. 195–205.
7 Krege, S. – Beyer, J. – Souchon. R. – et al.: European consensus confe­
rence on diagnosis and treatment of germ cell cancer: a report of the
second meeting of the European Germ Cell Cancer Consensus Group
(EGCCCG): part II. Eur Urol, 2008, 53 (3), s. 497–513.
8 Kondagunta, G. V. – Bacik, J. – Donadio, A., et al.: Combination of pa­
cli­taxel, ifosfamide, and cisplatin is an effective second-line therapy for
patients with relapsed testicular germ cell tumors. J Clin Oncol, 2005,
23 (27), s. 6549–6555.
9 Einhorn, L. H. – Williams, S. D. – Chamness, A., et al.: High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors.
N Engl J Med, 2007, 357 (4), s. 340–348.
10Fossa, S. D. – Bokemeyer, C. – Gerl, A., et al.: Treatment outcome
of pa­tients with brain metastases from malignant germ cell tumors.
­Cancer, 1999, 85, s. 988–997.
11Buchler, T. – Kubankova, P. – Boublikova, L., et al.: Detection of se­
cond malignancies during long-term follow-up of testicular cancer
sur­vi­vors. Cancer, 2011, 117, s. 4212–4218.
Současné možnosti léčby karcinomu slinivky břišní
MUDr. Michal Vočka | prof. MUDr. Luboš Petruželka, CSc.
Onkologická klinika 1. LF UK a VFN a ÚVN, Praha
1 Hidalgo, M.: Pancreatic Cancer. N Engl J Med, 2010, 362, s. 1605–1617.
2 Verdecchia, A. – Francisci, S. – Kunkler, I., et al.: Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet
Oncology, 2007, 8 (9), s. 784–796.
3 Roazzi, P. – Capocaccia, R. – Santaquilani, M. – Carrani, E.: Electronic
availability of EUROCARE-3 data: a tool for further analysis. Ann Oncol,
2003, 14 (dopl. 5), s. 150–155.
4 www.svod.cz.
5 Dušek, L., et al.: Czech Cancer Care in Numbers 2008–2009. Grada Publishing, Praha, 2009.
6 Hanash, S. M., et al.: Emerging molecular biomarkers-blood-based
strategies to detect and monitor cancer. Nat. Rev. Clin. Oncol, 2011, 8,
s. 142–150.
7 Abramson, M. A. – Jazag, A. – van der Zee, J. A. – Whang, E. E.: The
Molecular Biology of Pancreatic Cancer. Gastrointest Cancer Res, 2007,
1, s. 7–12.
8 Cascinu, S. – Falconi, M. – Valentini, V. – Jelic, S.: On behalf of the
ESMO Guidelines Working Group: Pancreatic cancer: ESMO Clinical
Practice Guidelines for diagnosis, treatment and follow-up. Annals of
Oncology, 2010, 21, s. 55–58.
9 Chang, D. K. – Johns, A. L., et al.: Margin Clearance and Outcome in
Resected Pancreatic Cancer. J Clin Oncol, 2010, 27, s. 2855–2862.
10Balcom, J. H. – Rattner, D. W. – Warshaw, A. L. – Chang, Y. – Fernandez-del, C. C.: Ten-year experience with 733 pancreatic resections:
changing indications, older patients, and decreasing length of hospitalization. Arch Surg, 2001, 136, s. 391–398.
11Birkmeyer, J. D. – Finlayson, S. R. – Tosteson, A. N. – Sharp, S. M. –
Warshaw, A. L. – Fisher, E. S.: Effect of hospital volume on in-hospital mortality with pancreaticoduodenectomy. Surgery, 1999, 125,
s. 250–256.
12Stocken, D. D. – Buchler, M. W. – Dervenis, C. – Bassi, C. – Jeekel, H. –
Klinkenbijl, J. H., et al.: Meta-analysis of randomised adjuvant therapy
trials for pancreatic cancer. Br J Cancer, 2005, 92, s. 1372–1381.
13GITSG. Further evidence of effective adjuvant combined radiation and
chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer, 1987, 59, s. 2006–2010.
14Klinkenbijl, J. H. – Jeekel, J. – Sahmoud, T. – van Pel, R. – Couvreur,
M. L. – Veenhof, C. H., et al.: Adjuvant radiotherapy and 5-fluorouracil
after curative resection of cancer of the pancreas and periampullary
region: phase III trial of the EORTC gastrointestinal tract cancer coope­
rative group. Ann Surg, 1999, 230, s. 776–782.
15Neoptolemos, J. P. – Dunn, J. A. – Stocken, D. D. – Almond, J. – Link,
K. – Beger, H., et al.: Adjuvant chemoradiotherapy and chemotherapy
in resectable pancreatic cancer: a randomised controlled trial. Lancet,
2001, 358, s. 1576–1585.
16Regine, W. F. – Winter, K. W. – Abrams, R. – Safran, H. – Hoffman,
J. P. – Konski, A., et al.: RTOG 9704 a phase III study of adjuvant pre
and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected
pancreatic adenocarcinoma. J Clin Oncol, 2006, 24, No. 18S: 4007.
17Ben-Josef, E. – Lawrence, T. S.: The importance of local kontrol in pancreatic cancer. Clin Oncol, 2012, 9, s. 9–10.
18Stathis, A. – Moore, M. J.: Advanced pancreatic carcinoma: current treat­ment and future challenges. Nat. Rev. Clin. Oncol, 7, 2010,
s. 163–172.
19Huguet, F. – Girard, N. – Guerche, C. S. – Hennequin, C. – Mornex,
F. – Azria, D.: Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin
Oncol, 2009, 27, s. 2269–2277.
20Heinemann, V. – Boeck, S. – Hinke, A. – Labianca, R. – Louvet, C.:
Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer, 2008, 8, s. 82–85.
21Conroy, T., et al.: FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. N Eng J Med, 2011, 364, s. 1817–1825.
22Tempero, M. A., et al.: Pancreatic cancer treatment and research: ­an
international expert panel discussion. Ann Oncol, 2011, s. 93–99.
23Philip, P., et al.: Phase III study of gemcitabine [G] plus cetuximab [C]
versus gemcitabine in patients [pts] with locally advanced or meta­
static pancreatic adenocarcinoma [PC]: SWOG S0205 study. J Clin
­Oncol, 2007, 25, s. a4509.
24Van Cutsem, E. – Vervenne, W. – Bennouna, J., et al.: Phase III ­trial
of bevacizumab in combination with gemcitabine and erlotinib in
patients with metastatic pancreaticcancer. J Clin Oncol, 2008, 27,
s. 2231–2237.
25Kindler, H. L. – Priberg, G. – Singh, D. A., et al.: Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.
J Clin Oncol, 2005, 23, s. 8033–8040.
26Van Cutsem, E. – van de Velde, H. – Karasek, P., et al.: Phase III trial of
gemcitabine plus tipifarnib compared with gemcitabine plus placebo
in advanced pancreatic cancer. J Clin Oncol, 2004, 22, s. 1430–1438.
27Moore, M. J., et al.: Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase
III Trial of the National Cancer Institute of Canada Clinical Trials Group.
J Clin Oncol, 2007, 25, s. 1960–1966.
28Pelzer, U. – Stieler, J., et al.: A randomised second line trial in patients
with gemcitabine refractory advanced pancreatic cancer- CONKO 003.
J Clin Onco, 2007, 25 (dopl.), s. 201.
29Harsha, H. C. – Kandasamy, K. – Ranganathan, P., et al.: A compendium of potential biomarkers of pancreatic cancer. PLoS Med, 2009, 6
(4), s. e1000046.
30Burris, H. A., et al.: J Clin Oncol, 1997, 15, s. 2403–2413.
31Conroy, T., et al.: ASCO, 2010, abstrakt 4010.
ACTA MEDICINAE 2/2012 ONKOLOGIE Kompletní literatura
Výživa onkologického pacienta
doc. MUDr. Miroslav Tomíška, CSc. Interní hematologická a onkologická klinika LF MU a FN, Brno
1 Andreyev, H. J. N. – Norman, A. R. – Oates, J. – Cunningham, D.: Why
do patients with weight loss have a worse outcome when undergoing
chemotherapy for gastrointestinal malignancies? Eur J Cancer, 1998,
34, s. 503–509.
2 Awad, S. – Tan, B. J. – Cui, H., et al.: Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric
cancer. Clin Nutrition, 2012, 31, s. 74–77.
3 Barber, M. D. – Ross, J. A. – Fearon, K. C. H.: Cancer cachexia. Surg
­Oncol, 1999, 8, s. 133–141.
4 Braga, M. – Gianotti, L. – Radaelli, G., et al.: Perioperative immunonutrition in patients undergoing cancer surgery: results of a randomized
doube-blind phase 3 trial. Arch Surg, 1999, 134 (4), s. 428–433.
5 Camps, C. – Iranzo, V. – Bremnes, R. M. – Sirera, R.: Anorexia-cachexia
syndrome in cancer: implications of the ubiquitin-proteasome pathway. Supp Care Cancer, 2006, 14, s. 1173–1183.
6 Davidson, W. – Ash, S. – Capra, S., et al.: Weight stabilisation is associated with improved survival duration and quality of life in unresectable pancreatic cancer. Clin Nutrition, 2004, 23, s. 239–247.
7 Fearon, K. C. H. – Barber, M. D. – Moses, A. G., et al.: Double-blind, placebo controlled, randomised study of eicosapentaenoic acid diester
in patients with cancer cachexia. J Clin Oncol, 2006, 24, s. 3401–3407.
8 Hoda, D. – Jatoi, A. – Burnes, J., et al.: Should patients with advanced,
incurable cancers ever be sent home with total parenteral nutrition? A singles institution´s 20-years experience. Cancer, 2005, 103,
s. 863–868.
9 Khalid, U. – Spiro, A. – Baldwin, C., et al.: Symptoms and weight loss
in patients with gastrointestinal and lung cancer at presentation. Sup­
por Care Cancer, 2007, 15, s. 39–46.
10McMillan, D. C. – Watson, W. S. – Preston, T. – McArdle, C. S.: Lean
body mass changes in cancer patients with weight loss. Clinical Nutri­
tion, 2000, 19, s. 403–406.
11Moses, A. W. G. – Slater, C. – Preston, T., et al.: Reduced total energy
expenditure and physical activity in cachectic patients with pancreatic
cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Cancer, 2004, 90, s. 996–1002.
12Nitenberg, G. – Raynard, B.: Nutritional support of the cancer patient:
issues and dilemmas. Critical Review in Oncology/Hematology, 2000, 34,
s. 137–168.
13Ovesen, L. – Allingstrup, L. – Hannibal, J. – Mortensen, E. L. – ­Hansen,
O. P.: Effect of dietary counselling on food intake, body weight, res­
ponse rate, survival, and quality of life in cancer patients undergoing
chemotherapy: A prospective, randomized study. J Clin Oncol, 1993,
11, s. 2043–2049.
14Ravasco, P. – Monteiro-Grillo, I. – Vidal, P. M., et al.: Dietary counselling improves patient outcomes: a prospective, randomized controlled
trial in colorectal cancer patients undergoing radiotherapy. J Clin On­
cology, 2005, 23, s. 1431–1438.
15Tisdale, M. J.: Cachexia in cancer patients. Nature Reviews, 2002, 2,
s. 862–871.
16Zadák, Z.: Enterální výživa u pacientů s nádorovým onemocněním.
In: Wilhelm, Z., et al.: Výživa v onkologii. Institut pro další vzdělávání
pracovníků ve zdravotnictví, Brno, 2001.
Současné možnosti léčby průlomové bolesti
onkologických pacientů
MUDr. Ondřej Sláma, Ph.D. Ambulance podpůrné a paliativní onkologie,
Klinika komplexní onkologické péče MOU, Brno
1 Davies, A. M. – Dickman, A. – Reid, C., et al.: The management of
cancer-related breakthrough pain: Recommendations of a taskgroup
of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. European Journal of Pain, 2009, 13,
s. 331–338.
2 Haugen, D. F. – Hjermstad, M. J. – Hagen, N., et al.: Assessment and
classification of cancer breakthrough pain: A systematic literature review. Pain, 2010, 149, s. 476–482.
3 Kabelka, L. – Lejčko, J. – Kozák, J. – Sláma, O.: Doporučený postup
pro léčbu průlomové nádorové bolesti. Farmakoterapie, 2011, 7 (5),
s. 521–523.
4 Portenoy, R. K. – Forbes, K. – Lussier, D. – Hanks, G.: Difficult pain
problems: an integrated approach. In: Doyle, D. – Hanks, G. – Cherny,
N. – Calman, K. (eds.): Oxford textbook of palliative medicine. Oxford,
Oxford University Press, 2004, s. 438–458.
5 Sláma, O. – Lejčko, J. – Kozák, J., et al.: Epidemiologie a léčba prů­lo­
mové bolesti u onkologických pacientů v ČR. Výsledky výzkumné­ho
projektu PARMA. Část 1. Prevalence a klinické charakteristiky průlo­mo­
vé bolesti. Bolest, 2011, 14 (1), s. 158–160.
6 Mercadante, S. – Villari, P. – Ferrera, P. – Casuccio, A.: Optimization
of opioid therapy for preventing incident pain associated with bone
metastases. J Pain Sympt Manage, 2004, 28, s. 505–510.
ACTA MEDICINAE 2/2012 ONKOLOGIE Kompletní literatura
Léčba olanzapinem u pacientů se schizofrenií
doc. MUDr. Klára Látalová, Ph.D. Klinika psychiatrie FN Olomouc, LF UP, Olomouc
1 Breier, A. – Meehan, K. – Birkett, M., et al.: A double-blind, placebocontrolled dose-response comparison of intramuscular olanzapine
and haloperidol in the treatment of acute agitation in schizophrenia.
Arch Gen Psychiatry, 2002, 59, s. 441–448.
2 Hill, A. L. – Sun, B. – Karagianis, J. L., et al.: Dose-associated changes
in safety and efficacy parameters observed in a 24-week maintenance
trial of olanzapine long-acting injection in patients with schizophrenia. BMC Psychiatry, 2011, 15, s. 11–28.
3 Kane, J. M. – Detke, H. C. – Naber, D., et al.: Olanzapine long-acting
injection: A 24-week, randomized, double-blind trial of maintenance
treatment in patients with schizophrenia. Am J Psychiatry, 2010, 167,
s. 181–189.
4 Komossa, K. – Rummel-Kluge, C. – Hunger, H., et al.: Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database
Syst Rev, 2010, 3, CD006654.
5 Lauriello, J. – Lambert, T. – Andersen, S., et al.: An 8-week, double
blind, randomized, placebo-controlled study of olanzapine long-acting­injection in acutely ill patients with schizophrenia. J Clin Psy­
chiatry, 2008, 69, s. 790–799.
6 Leucht, S. – Komossa, K. – Rummel-Kluge, C., et al.: A meta-analysis
of head-to-head comparisons of second-generation antipsychotics in
the treatment of schizophrenia. Am J Psychiatry, 2009, 166, s. 152–163.
7 Lieberman, J. A. – Stroup, T. S. – McEvoy, J. P., et al.: Effectiveness
of antipsychotic drugs in patiens with chronic schizophrenia. N Engl
J Med, 2005, 353, s. 1209–1223.
8 Meehan, K. – Zhang, F. – David, S. – Tohen, M., et al.: A double-blind,
randomized comparison of the efficacy and safety of intramuscular
injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol,
2001, 21, s. 389–397.
9 Meehan, K. M. – Wang, H. – David, S. R. – Nisivoccia, J. R., et al.: Comparison of rapidly acting intramuscular olanzapine, lorazepam, and
placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology, 2002, 26, s. 494–504.
10Wright, P. – Birkett, M. – David, S. R., et al.: Double-blind, placebocontrolled comparison of intramuscular olanzapine and intramuscular
haloperidol in the treatment of acute agitation in schizophrenia. Am
J Psychiatry, 2001, 158, s. 1149–1151.
Depresivní porucha a její léčba
prof. MUDr. Ján Praško, CSc. | doc. MUDr. Klára Látalová, Ph.D.
Klinika psychiatrie FN Olomouc, LF UP, Olomouc
1 American Psychiatric Association: Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psy­
chiatry, 2000, 157 (dopl.), s. 1–45.
2 Bauer, M. – Bschor, T. – Kuntz, D. – Berhöfer, A. – Stöhle, A. – Müller-Oerlinghausen, B.: Double blind, placebo controlled trial of the
use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. Am J Psychiatry, 2000,
157, s. 1429–1435.
3 Beck, A. T. – Rush, A. J. – Shaw, B. F. – Emery, G.: Cognitive Therapy of
Depression. New York, Guilford, 1979.
4 Clinical Guidelines for The Treatment of Depressive Disorders (Clinical Practice Guidelines). The Canadian Journal of Psychiatry, 2001, 46
(dopl. 1), s. 91.
5 Crismon, M. L. – Trivedi, M. – Pigott, T. A. – Rush, A. J. – Hirschfeld,
R. M. – Kahn, D. A. – De Battista, C. – Nelson, J. C. – Nierenberg, A.
A. – Sackeim, H. A. – Thase, M. E.: The Texas Algorithm Project: report
of the Texas Consensus Conference Panel on medication treatment
of major depressive disorder. J Clin Psychiatry, 1999, 60, s. 142–156.
6 El-khalili, N. – Joyce, M. – Atkinson, S.: Adjunctive extended-release
quetiapine fumarate in patients with major depressive disorder and ina­
dequate antidepressant response. 16st Annual Meeting of the American
Psychiatrie Association, Washington DC, USA, 2008.
7 Frank, E. – Prien, R. F. – Jarrett, R. B. – Keller, M. B. – Kupfer, D. J. –
Lavori, P. W. – Rush, A. J. – Weissmann, M. M.: Conceptualization and
rationale for consensus definitions of terms in major depressive disorder. Arch Gen Psychiatry, 1991, 48, s. 851–855.
8 Geddes, J. R. – McCarney, S. M. – Davies, C. – Furukawa, T. A. – Kupfer, D. J. – Goodwin, G. M.: Relapse prevention with antidepressant
drug treatment in depressive disorder: a systematic review. Lancet,
2003, 361, s. 653–661.
9 Kessler, R. C. – Berglund, P. – Demler, O., et al.: The epidemiology
of major depressive disorder: results from the National Comorbidity
Survey Replication (NCS-R). JAMA, 2003, 289, s. 3095–3105.
10McPherson, S. – Cairns, P. – Carlyle, J. – Shapiro, D. A. – Richardson,
P. – Taylor, D.: The effectiveness of psychological treatments for treatment-resistant depression: a systematic review. Acta Psychiatr Scand,
2005, 111 (5), s. 331–340.
11Mezinárodní klasifikace nemocí. 10. revize. Duševní poruchy a poruchy
chování: Popisy klinických příznaků a diagnostická vodítka (přeloženo
z anglického originálu). Praha, Psychiatrické centrum, 1992, Zprávy
č. 102.
12Montgomery, S. – Cutler, A. – Lazarus, E.: Extended release quetiapine­
fumarate monotherapy in the treatment of patients with major depressive disorder. 16th European Congress of Psychiatry, Nice, Francie,
2008.
13Moore, R. G. – Garland, A.: Cognitive Therapy for Chronic and Persistent
Depression. Chichester, John Wiley and Sons, 2003.
14Murray, C. J. – Lopez, A. D.: Alternative projections of mortality and
disability by cause 1990-2020: Global Burden of Disease Study. Lancet,
1997, 349, s. 1498–1504.
15Praško, J.: Bright light therapy. Neuroendocrinology Letters, 2008, 29
(dopl. 1), s. 33–64.
16Quitkin, F. M. – McGrath, J. P. – Stewart, J. W.: Chronological milestones to guide drug change: when should clinician switch antidepressant? Arch Gen Psychiatry, 1996, 53, s. 785–792.
17Rush, A. J. – Trivedi, M. H. – Wisniewski, S. R. – Nierenberg, A. A. –
Stewart, J. W. – Warden, D., et al.: Acute and longer-term outcomes
in depressed outpatients requiring one or several treatment steps:
a STAR*D report. Am J Psychiatry, 2006, 163 (11), s. 1905–1917.
18Segal, Z. – Williams, J. M. – Teasdale, J.: Mindfulness -based cognitive
therapy for depression. New York, The Guilford Press, 2002.
19Thase, M. E. – Friedman, E. S. – Howland, R. H.: Management of treatment-resistant depression: psychotherapeutic perspectives. J Clin Psy­
chiatry, 2001, 62 (dopl. 18), s. 18–24.
ACTA MEDICINAE 2/2012 ONKOLOGIE Kompletní literatura
20Thase, M. E.: Effects of venlafaxine on blood pressure: a metanalysis
of original data from 3744 depressed patients. J Clin Psychiatry, 1998,
59, s. 502–508.
21Thase, M. E.: Relapse and recurrence in unipolar major depression:
Short-term and long-term approaches. J Clin Psychiatry, 1990, 5 (dopl.),
s. 51–57.
22Weisler, R. – Joyce, M. – Mc Gill, L.: Extended release quetiapine fumu­
rate monotherapy for major depressive disorder (MDD): a double-blind
placebo-controlled study. American Psychiatric Association, Washington D. C., USA, 2008.
23Weissman, M. M. – Leaf, P. J. – Tischler, G. L., et al.: Affective disorders
in five United States communities. Psychol Med, 1988, 18, s. 141–153.
24WHO: WHO Report 2001: Mental Health. New Hope: New Understanding.
2001, kapitola 2: Burden of Mental and Behavioral Disorders.
25World Health Organization, Mental Health Collaborating Centers, 1989.
Role mikroRNA při vzniku nádorů a možnosti jejich využití v léčbě
prof. Ing. Jaroslav Petr, DrSc. Výzkumný ústav živočišné výroby, Praha
1 Lujambio, A. – Lowe, S. W.: The microcosmos of cancer. Nature, 2012,
484, s. 347–355.
2 Calin, G. A. – Dumitru, C. D. – Shimizu, M. – Bichi, R. – Zupo, S. –
Noch, E. – Adler, H. – Rattan, S. – Keating, M. – Rai, K. – Rassenti, L. –
Kipps, T. – Negrini, M. – Bullrich, F. – Croce, C. M.: Frequent deletions
and down-regulation of micro- RNA genes miR15 and miR16 at 13q14
in chronic lymphocytic leukemia. Proceedings of the National Academy
of Sciences, 2002, 99, s. 15524–15529.
3 Lu, J. – Getz, G. – Miska, E. A. – Alvarez-Saavedra, E. – Lamb, J. – Peck,
D. – Sweet-Cordero, A. – Ebert, R. L. – Mak, R. H. – Ferrando, A. A. –
Downing, J. R. – Jacks, T. – Horvitz, H. R. – Golub, T. R.: MicroRNA expression profiles classify human cancers. Nature, 2005, 435, s. 834–838.
4 Yanaihara, N. – Caplen, N. – Bowman, E. – Seike, M. – Kumamoto,
K. – Yi, M. – Stephens, R. M. – Okamoto, A. – Yokota, J. – Tanaka, T. –
Calin, G. A. – Liu, C.-G. – Croce, C. M. – Harris, C. C.: Unique microRNA
molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell,
2006, 9, s. 189–198.
5 Mitchell, P. S. – Parkin, R. K. – Kroh, E. M. – Fritz, B. R. – Wyman, S. K. –
Pogosova-Agadjanyan, E. L. – Peterson, A. – Noteboom, J. – O‘Briant,
K. C. – Allen, A. – Lin, D. W. – Urban, N. – Drescher, C. W. – Knudsen,
B. S. – Stirewalt, D. L. – Gentleman, R. – Vessella, R. L. – Nelson, P.
S. – Martin, D. B. – Tewari, M.: Circulating microRNAs as stable bloodbased markers for cancer detection. Proceedings of the National Aca­
de­my of Sciences, 2008, 105, s. 10513–10518.
6 Thomson, J. M. – Newman, M. – Parker, J. S. – Morin-Kensicki, E. M. –
Wright, T. – Hammond, S. M.: Extensive post-transcriptional regulation
of microRNAs and its implications for cancer. Genes & Development,
2006, 20, s. 2202–2207.
7 Chang, T.-C. – Yu, D. – Lee, Y.-S. – Wentzel, E. A. – Arking, D. E. – West,
K. M. – Dang, C. V. – Thomas-Tikhonenko, A. – Mendell, J. T.: Widespread microRNA repression by Myc contributes to tumorigenesis.
Nature Genetics, 2008, 40, s. 43–50.
8 Johnson, S. M. – Grosshans, H. – Shingara, J. – Byrom, M. – Labourier, E. – Reinert, K. L. – Brown, D. – Slack, F. J.: RAS Is regulated by the
let-7 MicroRNA Family. Cell, 2005, 120, s. 635–647.
9 He, L. – He, X. – Lowe, S. W. – Hannon, G. J.: microRNAs join the p53
network – another piece in the tumor-suppression puzzle. Nature
­Reviews Cancer, 2007, 7, s. 819–822.
10Su, X. – Chakravarti, D. – Cho, M. S. – Liu, L. – Gi, Y. J. – Lin, Y.-L. –
Leung, M. L. – El-Naggar, A. – Creighton, C. J. – Suraoka, M. B. – Wistuba, I. – Flores, E. R.: TAp63 suppresses metastasis through coordinate
regulation of Dicer and miRNAs. Nature, 2010, 467, s. 986–990.
11Godlewski, J. – Nowicki, M. O. – Bronisz, A. – Nuovo, G. – Palatini,
J. – De Lay, M. – Van Brocklyn, J. – Ostrowski, M. C. – Chiocca, E. A. –
Lawler, S. E.: MicroRNA-451 regulates LKB1/AMPK signaling and allows
adaptation to metabolic stress in glioma cells. Molecular Cell, 2010, 37,
s. 620–632.
12Anand, S. – Majeti, B. K. – Murphy, L. M. – Mukthavaram, R. – Scheppke, L. – Huang, M. – Shields, D. J. – Lindquist, J. N. – Lapinski, P. E. –
King, P. D. – Weis, S. M. – Cheresh, D. A.: MicroRNA-132–mediated loss
of p120RasGAP activates the endothelium to facilitate pathological
angiogenesis. Nature Medicine, 2010, 16, s. 909–914.
ACTA MEDICINAE 2/2012 ONKOLOGIE Kompletní literatura